$RPID

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Sees Large Increase in Short Interest

Rapid Micro Biosystems (NASDAQ:RPID) experienced an 18.9% increase in short interest, reaching 377,502 shares as of March 31st, indicating a 1.4 days-to-cover ratio. This occurred despite recent insider selling by the COO and CFO, who disposed of shares worth over $73,000 in March. The company also reported missing EPS estimates but exceeded revenue expectations for the last quarter, with a current market capitalization of approximately $103.7 million.

Original reporting
MarketBeat · MarketBeat
Published Apr 18, 2026, 10:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 18, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Sees Large Increase in Short Interest — source image
Decision brief

The 30-second read

$RPIDBearishMed
01

Why it matters

The combination of insider activity and rising short interest suggests increased caution among traders, possibly leading to short-term downward pressure.

02

Market read

The news is relevant for traders focusing on biotech stocks, especially those with short-term trading strategies.

03

What to watch

Potential upcoming catalysts or sector-wide recovery could offset current bearish signals.

Timing: short-term

Background

Rapid Micro Biosystems recently reported mixed earnings and experienced insider selling, alongside a notable increase in short interest, signaling potential bearish sentiment.

Company-level read

Ticker impact

$RPIDBearishMedium confidence
Context

The news about increased short interest and insider selling may impact RPID's stock price.

Expected impact

Potential short-term decline or increased volatility due to bearish sentiment and insider selling, with a possible rebound if fundamentals improve.

Evidence & confidence

The rise in short interest suggests traders are betting against the stock, but the mixed earnings and insider activity present a complex picture. Technical indicators and broader market conditions should be monitored for confirmation.

Market effects

The biotech and life sciences sector may see increased scrutiny or volatility due to company-specific news.

Limited regional impact; primarily affects NASDAQ-listed biotech stocks.

Low; company-specific news unlikely to influence global markets.

Counterpoint

The insider selling might be routine and not indicative of future performance; the earnings miss could be temporary.

Key entities

  • Rapid Micro Biosystems

    A biotech company specializing in microbiology automation.

Related articles

$RPIDMed

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems (NASDAQ: RPID) reported Q2 margin improvements, with consumables margins up 17 points YoY and service margin at a record 49%. Operating expenses rose to $13.5M. Net loss was $12.9M ($0.27/share). The company reaffirmed 2026 revenue guidance of $37M-$41M, raised validation targets, and projected Q3 revenue at least $9.5M.

$RPIDMedAI 8/10

Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 total revenue of $8.1 million, up 11% year over year. Recurring revenue rose 14% to $5.0 million, 63% of total. Gross margin was a record 15%. The company reaffirmed 2026 revenue guidance of $37.0 million to $41.0 million and gross margin near 20%, and raised validation guidance to at least 27.

$RPIDMed

RAPID MICRO BIOSYSTEMS, INC. (RPID): Results of Operations and Financial Condition

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rpid-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results • Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 ◦ Achieved a significa

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).